Journals / Online Türk Sağlık Bilimleri Dergisi / 2026 / Cilt: 11 Sayı: 2

The Comparison of Hotspot Mutations in Primary and Metastatic Melanoma Cell Lines

Primer ve Metastatik Melanom Hücre Hatlarında Sıcak Nokta Mutasyonlarının Karşılaştırılması

Canan Doğan(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0009-0008-6496-7882
Özen Özensoy Güler(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-0389-9624
Deniz Atakol(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-3858-844X
Seher Şahin(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ, TIP FAKÜLTESİ)0009-0006-9163-0762
Ender Şimşek(ANKARA YILDIRIM BEYAZIT ÜNİVERSİTESİ)0000-0001-6635-4125
Pages
115–121
Publication Date
2026-06-21
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: According to the results of our research, we think that the occurrence of BRAF mutations in primary melanoma indicates that this gene is effective in the progression and development of melanoma, and the mutation occurring in the VHL gene of metastatic melanoma might be effective in carcinogenesis via the HIF pathway.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Melanoma is a disease that develops as a result of UV radiation acting as a mutagenic risk factor and causes various genetic changes.
📊
Key Findings & Data:In our study, we aimed to determine the changes in human cancer-related genes between Primary Melanoma (WM115) and Metastatic Melanoma (SK-MEL-30) cell lines.
💡
Conclusion & Impact:Conclusions: According to the results of our research, we think that the occurrence of BRAF mutations in primary melanoma indicates that this gene is effective in the progression and development of melanoma, and the mutation occurring in the VHL gene of metastatic melanoma might be effective in carcinogenesis via the HIF pathway.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Hotspot mutasyonu · melanom · NOTCH

Abstract

Objective: Melanoma is a disease that develops as a result of UV radiation acting as a mutagenic risk factor and causes various genetic changes. In our study, we aimed to determine the changes in human cancer-related genes between Primary Melanoma (WM115) and Metastatic Melanoma (SK-MEL-30) cell lines. Materials and Methods: Among the proto-oncogenes and tumor suppressor genes, 50 genes associated with human cancers were selected. Afterwards, the changes of hotspot mutations occurring in 50 genes between the two cell lines were examined using the Ion Ampliseq Cancer Hotspot DNA Panel v2 gene panel. Results: A mutation increase was observed in the metastatic melanoma cell line compared to the primary cell line. 4 Variant of Uncertain Significance (VUS), 3 benign and 2 pathogenic mutations were detected in the WM115 cell line. Pathogenic mutations have been identified in the BRAF proto-oncogene. In the SK-MEL-30 cell line, 24 VUS, 1 benign, and 1 possible pathogenic mutation (in the VHL gene) were observed. Conclusions: According to the results of our research, we think that the occurrence of BRAF mutations in primary melanoma indicates that this gene is effective in the progression and development of melanoma, and the mutation occurring in the VHL gene of metastatic melanoma might be effective in carcinogenesis via the HIF pathway. In addition, most of the VUS mutations of metastatic melanoma occurred in the RET and NOTCH pathways. The accumulation of mutations in genes involved in these pathways may contribute to the development of metastasis.

Özet

Amaç: Melanom, UV radyasyonunun mutajenik bir risk faktörü olarak hareket etmesi sonucu gelişen ve çeşitli genetik değişikliklere neden olan bir hastalıktır. Çalışmamızda Primer Melanom (WM115) ve Metastatik Melanom (SK-MEL-30) hücre hatları arasında insan kanser ilişkili genlerindeki değişiklikleri belirlemeyi amaçladık. Materyal ve Metot: Proto-onkogenler ve tümör baskılayıcı genler arasından insan kanserleriyle ilişkili 50 gen seçildi. Daha sonra iki hücre hattı arasında 50 gende oluşan hotspot mutasyonlarının değişimleri Ion Ampliseq Cancer Hotspot DNA Panel v2 gen paneli kullanılarak incelendi. Bulgular: Metastatik melanom hücre hattında primer hücre hattına göre mutasyon artışı gözlendi. WM115 hücre hattında 4 adet Önemi Belirsiz Varyant (VUS), 3 adet benign ve 2 adet patojenik mutasyon tespit edildi. BRAF proto-onkogeninde patojenik mutasyonlar tanımlanmıştır. SK-MEL-30 hücre hattında 24 VUS, 1 iyi huylu ve 1 olası patojenik mutasyon (VHL geninde) gözlendi. Sonuç: Araştırmamızın sonuçlarına göre, primer melanomda BRAF mutasyonunun görülmesinin, bu genin melanomun ilerlemesi ve gelişiminde etkili olduğunu, metastatik melanomda ise VHL geninde oluşan mutasyonun ise HIF yolu ile karsinogenezde etkili olabileceğini düşünmekteyiz. Ek olarak, metastatik melanomun VUS mutasyonlarının çoğu RET ve NOTCH yollarında meydana geldi. Bu yollarda yer alan genlerdeki mutasyonların birikmesi, metastaz gelişimine katkıda bulunabilir.

🔖

Cite This Article

Doğan, C., Güler, Ö. Ö., Atakol, D., Şahin, S., Şimşek, E., *, E. Ş. (2026). The Comparison of Hotspot Mutations in Primary and Metastatic Melanoma Cell Lines. Online Türk Sağlık Bilimleri Dergisi, Cilt: 11 Sayı: 2, 115–121. https://doi.org/10.26453/otjhs.1738044

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (24)

  1. Teixido C, Castillo P, Martinez-Vila C, Arance A, Alos L. Molecular Markers and Targets in Melanoma. Cells. 2021;10(9):2320. doi:10.3390/cells10092320
  2. Ribeiro Moura Brasil Arnaut J, Dos Santos Guimarães I, Evangelista Dos Santos AC, de Moraes Lino da Silva F, Machado JR, de Melo AC. Molecular landscape of Hereditary Melanoma. Crit Rev Oncol Hematol. 2021;164:103425. doi:10.1016/j.critrevonc.2021.103425
  3. Read J, Wadt KA, Hayward NK. Melanoma genetics. J Med Genet. 2016;53(1):1-14. doi:10.1136/jmedgenet-2015-103150
  4. Rhee JK, Yoo J, Kim KR, et al. Identification of Local Clusters of Mutation Hotspots in Cancer-Related Genes and Their Biological Relevance. IEEE/ACM Trans Comput Biol Bioinform. 2019;16(5):1656-1662. doi:10.1109/TCBB.2018.2813375
  5. Zhu K, Liu Q, Zhou Y, et al. Oncogenes and tumor suppressor genes: comparative genomics and network perspectives. BMC Genomics. 2015;16(Suppl 7):S8. doi:10.1186/1471-2164-16-S7-S8
  6. Kontomanolis EN, Koutras A, Syllaios A, et al. Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. Anticancer Res. 2020;40(11):6009-6015. doi:10.21873/anticanres.14622
  7. Joyce C, Rayi A, Kasi A. Tumor-Suppressor Genes. 2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan 2025.
  8. Güvenç C, Neckebroeck F, Antoranz A, Garmyn M, van den Oord J, Bosisio FM. Bona Fide Tumor Suppressor Genes Hypermethylated in Melanoma: A Narrative Review. Int J Mol Sci. 2021;22(19):10674. Published 2021 Oct 1. doi:10.3390/ijms221910674
  9. OncoKB™. Cancer gene list. https://www.oncokb.org/cancer-genes. Accessed August 5, 2024.
  10. Thermo Fisher Scientific. Ion AmpliSeq™ Cancer Hotspot Panel v2. https://www.thermofisher.com/order/catalog/product/4475346#/4475346. Accessed August 5 2024.
  11. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. doi:10.1038/gim.2015.30
  12. Doğan C. Comparison of hotspot mutations in primary and metastatic melanoma cell lines. Master’s thesis. Ankara Yildirim Beyazit University; 2022.
  13. Alicea GM, Rebecca VW. Emerging strategies to treat rare and intractable subtypes of melanoma. Pigment Cell Melanoma Res. 2021;34(1):44-58. doi:10.1111/pcmr.12880
  14. Hessler M, Jalilian E, Xu Q, et al. Melanoma Biomarkers and Their Potential Application for In Vivo Diagnostic Imaging Modalities. Int J Mol Sci. 2020;21(24):9583. Published 2020 Dec 16. doi:10.3390/ijms21249583
  15. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239-271. doi:10.1146/annurev-pathol-012513-104658
  16. Śmiech M, Leszczyński P, Kono H, Wardell C, Taniguchi H. Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. Genes (Basel). 2020;11(11):1342. doi:10.3390/genes11111342
  17. Ritterhouse LL, Barletta JA. BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol. 2015;32(5):400-408. doi:10.1053/j.semdp.2015.02.010
  18. Castellani G, Buccarelli M, Arasi MB, et al. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Cancers (Basel). 2023;15(16):4026. doi:10.3390/cancers15164026
  19. Gläsker S, Neumann HPH, Koch CA, Vortmeyer A. Von Hippel-Lindau Disease. In: Feingold KR, Ahmed SF, Anawalt B, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2018.
  20. Hudler P, Urbancic M. The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis. Genes (Basel). 2022;13(2):362. doi:10.3390/genes13020362
  21. Badoiu SC, Greabu M, Miricescu D, et al. PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis. Int J Mol Sci. 2023;24(9):8391. doi:10.3390/ijms24098391
  22. Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. doi:10.1038/nrdp.2017.9
  23. Kim JY, Cho H, Yoo J, et al. HDAC8 Deacetylates HIF-1α and Enhances Its Protein Stability to Promote Tumor Growth and Migration in Melanoma. Cancers (Basel). 2023;15(4):1123. doi:10.3390/cancers15041123
  24. Kwong A, Ho CYS, Shin VY, Au CH, Chan TL, Ma ESK. How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer? BMC Med Genomics. 2022;15(1):122. doi:10.1186/s12920-022-01270-4